FDA 2003 wrap-up
This article was originally published in The Tan Sheet
Executive Summary
Agency issued more than 500 warning letters, opened 393 criminal cases and caused 341 arrests and 199 convictions amounting to more than $800 mil. "in fines and restitution" in fiscal year 2003, according to a Jan. 13 1white paper tallying the year's activity. Other highlights include the ephedra ban announcement (marking the first enforcement action under DSHEA), bioterror prevention food safety regulations, the CFSAN Adverse Event Reporting System and the proposed rule on the long-awaited dietary supplement GMPs...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.